Literature DB >> 8252508

Multicenter randomized trial comparing Zoladex with Zoladex plus flutamide in the treatment of advanced prostate cancer. Survival update. International Prostate Cancer Study Group.

C J Tyrrell1, J E Altwein, F Klippel, E Varenhorst, G Lunglmayr, F Boccardo, I M Holdaway, J M Haefliger, J P Jordaan, M Sotarauta.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8252508     DOI： 10.1002/1097-0142(19931215)72:12+<3878::aid-cncr2820721723>3.0.co;2-l

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  3 in total

1.  COOPERATIVE GROUP TRIALS - SOUTHWEST ONCOLOGY GROUP (SWOG) INNOVATIONS IN ADVANCED PROSTATE CANCER.

Authors:  Tanya B Dorff; Cathy M Tangen; E David Crawford; Daniel P Petrylak; Celestia S Higano; Derek Raghavan; David I Quinn; Nicholas J Vogelzang; Ian M Thompson; Maha H A Hussain
Journal:  Ther Adv Med Oncol       Date:  2009       Impact factor: 8.168

2.  Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346).

Authors:  Catherine M Tangen; Maha H A Hussain; Celestia S Higano; Mario A Eisenberger; Eric J Small; George Wilding; Bryan J Donnelly; Paul F Schelhammer; E David Crawford; Nicholas J Vogelzang; Isaac J Powell; Ian M Thompson
Journal:  J Urol       Date:  2012-08-22       Impact factor: 7.450

3.  Maximal androgen blockade for the treatment of metastatic prostate cancer--a systematic review.

Authors:  H Lukka; T Waldron; L Klotz; E Winquist; J Trachtenberg
Journal:  Curr Oncol       Date:  2006-06       Impact factor: 3.677
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.